Eli Lilly completed the acquisition of Dermira for $1.1bn.

Eli Lilly and Company, a manufacturer of pharmaceutical products, completed the acquisition of Dermira, a biopharmaceutical company for $1.1bn. "We are pleased to complete the acquisition of Dermira, and look forward to continuing their important work to develop new therapeutic options for patients with chronic skin conditions," Patrik Jonsson, Lilly Senior Vice President.